Lateral flow immunoassay

Up to 10-fold increase in assay sensitivity

BBI Solutions has launched Morffi, a novel conjugate blocking technology that enhances signal intensity and improves the sensitivity of lateral flow immunoassaysThe technology, developed in-house by BBI Solutions scientists, improves the limit of detection of an assay, providing an increase in sensitivity of up to ten times and a faster time to result.

(L-R) Dan Laxton, Robert Webb, Jonathan Thomas, Lowri Cope.
(L-R) Dan Laxton, Robert Webb, Jonathan Thomas, Lowri Cope.

Lateral flow immunoassays (LFIs) rely on the specific interaction between the analyte of interest and an immobilised binding partner, such as an antibody, antigen or enzyme. To improve performance, a ‘blocking’ agent is bound to unoccupied conjugation sites on the reporter label, preventing nonspecific binding. However, the most commonly used conjugate blocker, BSA cross-reacts with human serum albumin-binding antibodies, bovine and other animal-origin targets, and exhibits lot-to-lot variability. Its relatively large size can also lead to steric hindrance affecting the detection of the target molecule. The proprietary Morffi technology overcomes these issues1. Due to its size in comparison to BSA, it improves the availability of analyte-specific binding partners on the surface of the reporter label, increasing the signal intensity and sensitivity of the assay. Morffi has been successfully tested with over 30 conjugates to date, clearly demonstrating its suitability for a range of LFIs.

Find out more about BBI Solutions on www.bbisolutions.com


1 Morgan West, Ffion Walters, Shaun Phillips and Darren Rowles; Enhanced performance of a lateral flow assay. Use of a novel conjugate blocking technology to improve performance of a gold nanoparticle-based lateral flow assay. http://bit.ly/morffiwhitepaper

Source: BBI Solutions

28.11.2016

Read all latest stories

Related articles

Photo

Improvement of cardiac care

Rapid myocardial infarction verification

The use of troponin assays to rule in or rule out myocardial infarction (MI) rapidly is critical on several levels. The quick result can reassure the patient that they have not had a heart attack and…

Photo

Lab equipment

Atellica Solution gets 'thumbs up' from early adopters

Clinical laboratories are challenged to meet greater testing demands, improve efficiency, and deliver reliable, high-quality results, while facing an increasing shortage of skilled employees and…

Photo

Immunoassay and clinical chemistry analyzers

This is why laboratories worldwide adopt the Atellica Solution

LBM Bioesterel in France, Arcispedale S. Maria Nuova in Italy and Friarage Hospital in the United Kingdom are among the first laboratories to install the Atellica Solution immunoassay and clinical…

Related products

Beckman Coulter – Anti-Mullerian Hormone (AMH)

Immunochemistry

Beckman Coulter – Anti-Mullerian Hormone (AMH)

Beckman Coulter, Inc.
FUJIFILM Wako - μTASWako i30

Immunoassays

FUJIFILM Wako - μTASWako i30

Wako Chemicals GmbH
Siemens Healthineers – BN II System

Plasma Protein Testing

Siemens Healthineers – BN II System

Siemens Healthineers
Siemens Healthineers – Dimension EXL Chemistry Systems

Integrated Systems

Siemens Healthineers – Dimension EXL Chemistry Systems

Siemens Healthineers
AB Medical – V-Tube Clot Activator with Gel

Clinical Chemistry

AB Medical – V-Tube Clot Activator with Gel

AB Medical V-Tube
Alsachim, a Shimadzu group company – Dosimmune

Clinical Chemistry

Alsachim, a Shimadzu group company – Dosimmune

Alsachim, a Shimadzu Group Company